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Acute liver failure affects previously healthy and often young people and has a very high mortality due 
to rapid multi-organ failure. The diagnosis is based on the presence of coagulopathy (International 
normalized ratio >2 or prothrombin rate <50%) and hepatic encephalopathy within 8 weeks of onset 
of jaundice in patients with no previous liver disease (1).
In resource-constrained developing countries, hepatitis A, B, and E infections, traditional medi-
cines (2), drugs, herbal supplements (3), and halothane (4) are the main causes. Even though liver 
transplantation is the treatment of choice nowadays, the survival rate without liver transplantation in 
adults is as high as 40% in high-income countries (5, 6). Unfortunately, it is much lower in develop-
ing countries (7) where cases are diagnosed too late or considered untreatable in the absence of a 
transplant center.
We propose a practical approach that can be used in Intensive Care Unit-equipped hospitals in 
resource-constrained countries to try and reduce the high mortality rate where liver transplantation 
is not available.
Patients admitted to general medical wards with signs or symptoms of acute liver failure should be 
screened for acute A, B, E, and possibly D virus hepatitis infections, for anti-nuclear and anti-smooth 
muscle autoantibodies (when possible) and for recent acetaminophen use, and prothrombin time 
should be immediately determined. Infections (typhoid fever, leptospirosis, rickettsial fever, falci-
parum malaria, and tuberculosis), which may mimic the presentation of acute liver failure should 
be excluded; high grade fever, splenomegaly, normal international normalized ratio, mild alanine 
aminotransferase and aspartate aminotransferase elevation help to exclude acute liver failure (8). 
As bacterial infections are associated with increased death rates (9), blood and urine cultures should 
be routinely checked at admission in all patients with acute liver failure. Good infection control 
measures are mandatory to reduce the risk of nosocomial sepsis.
Patients initially fully oriented can progress in few hours to acute delirium with agitation and 
then coma with response to painful stimuli only; thus, they should be assessed as soon as possible 
after admission using the West Haven Criteria (10), which have four grades: Grade I – lack of aware-
ness, inverted sleep pattern, euphoria or anxiety, and shortened attention span; Grade II – lethargy 
or apathy, minimal disorientation for time or place, subtle personality change, and inappropriate 
behavior; Grade III – somnolence to semi stupor but responsive to verbal stimuli, confusion, and 
gross disorientation; and Grade IV – coma.
Patients with Grade I or II encephalopathy should be intubated and ventilated in case of sudden 
deterioration in consciousness level and transferred to the Intensive Care Unit. If not intubated, 
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attention must be paid to aggressive behavior, hyperreflexia, 
and ankle clonus as they predict progression to Grade III–IV 
coma and development of severe brain edema (11). Appropriate 
intensive care can reduce the incidence of severe encephalopathy 
and intracranial hypertension, which develops more frequently 
in younger patients (whose skull is tighter), in patients with renal 
dysfunction and in those requiring inotropic support for cardiac 
failure (12). The patients should be kept in a 20°–30° head-up 
position to decrease intracranial pressure and reduce the risk of 
aspiration pneumonia. Fluid should be restricted to two-third 
maintenance and glucose levels maintained at >4.0  μmol/l; 
gastroprotective drugs (e.g., ranitidine and sucralfate) should be 
used for prevention of gastrointestinal bleeding, and sepsis should 
be prevented with broad spectrum antibiotics. Large-volume 
infusions of hypotonic fluids, which may result in hyponatremia 
and cerebral swelling, should be avoided. Due to the high protein 
catabolism, 1.0–1.5 g of enteral protein/kg/day can be given with 
blood ammonia levels monitoring.
Antifungal therapy should be started in patients who do 
not improve with antibiotics. Fever may favor development of 
cerebral edema, by increasing body metabolism and production 
of ammonia, and its cerebral uptake and metabolism. Body tem-
perature should be kept at 35–36°C using external cooling and 
suppressing shivering.
Routine computerized tomography scan to detect brain 
edema should not be performed as moving the patient to the 
scanner might facilitate increase in intracranial pressure; com-
puterized tomography scan (where available) should be done 
only when focal neurological signs or pupillary abnormalities 
(suggesting intracranial bleeding or cerebral herniation) are 
present. Cerebral edema can be diagnosed clinically based on 
the presence of spontaneous decerebrate posturing alone or two 
of the following: hypertension, bradycardia, pupillary changes, 
neurogenic hyperventilation (13). For clinical signs of increased 
intracranial pressure, a bolus of intravenous hypertonic saline (at 
a dose of 20 ml of 30% sodium chloride, keeping serum sodium 
at <150  mmol/l) or mannitol (2  ml of 20% solution/kg b.w.) 
should be used.
Correction of coagulopathy is indicated only before an inva-
sive procedure (e.g., insertion of a central line); indeed, the risk 
of hemorrhage correlates more with the severity of thrombocy-
topenia rather than coagulopathy. The presence of disseminated 
intravascular coagulation usually indicates sepsis, which must be 
considered also in case of unexplained blood pressure decrease, 
urinary output drop, worsening encephalopathy, and develop-
ment of severe acidosis.
It is very important to anticipate and prevent renal failure 
by maintaining circulating volume with colloid or fresh frozen 
plasma (if available). Extracorporeal renal support in the form of 
hemofiltration may be necessary (when available), if there is an 
acute renal failure or concern about fluid management.
As for etiology-specific therapies, N-acetyl-cysteine adminis-
tration is the treatment of choice for acetaminophen-related acute 
liver failure and can be effective also in non-acetaminophen acute 
liver failure with low grade encephalopathy (14). Nucleoside 
analogs can be employed in hepatitis B virus-related and corticos-
teroids in severe autoimmune hepatitis-related acute liver failure 
but are of dubious influence on prognosis (15).
A procedure that could be investigated as an additional 
treatment for acute liver failure is temporary partial portal vein 
arterialization [reviewed in Ref. (16)], which can be performed 
through mesenteric vessel anastomosis or an extracorporeal 
device (that withdraws blood from the femoral artery and return 
it in the portal venous system through the umbilical vein). The 
procedure could stimulate hepatocyte regeneration by supplying 
extra oxygen to the liver to match the increased metabolic demand 
of the regenerating cells and by increasing portal pressure (which 
can activate regeneration) (17). The success in animal models 
(18, 19) and in some acute liver failure cases (16) indicates that 
this simple-to-perform procedure merits further investigation in 
patients with acute liver failure and might be successful particu-
larly in cases where this is due to drugs or toxics. Of course, it 
should be applied early enough in the course of the disease and 
when the patient does not meet, yet, the King’s College Hospital 
criteria for liver transplantation (20).
In conclusion, acute liver failure should not be considered 
untreatable without liver transplantation; chances of survival can 
be increased even in resource-constrained developing countries 
if patients are appropriately managed.
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